A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma

Not Recruiting

Trial ID: NCT00211185


Study of ONTAK and CHOP (chemotherapy drugs) to find out their ability to make Peripheral T-cell lymphoma disappear (for any period of time) and potentially lengthen life. The study will also compare what kind of side effects these drugs cause and how often they occur. The hypothesis is that patients with newly diagnosed peripheral T-Cell lymphoma, when given ONTAK + CHOP, will tolerate the treatment and will have a 20% improvement in response rate when compared to CHOP alone.

Official Title

A Pilot Phase II Study to Determine the Safety and Efficacy of the Combination of ONTAK With CHOP in Peripheral T-Cell Lymphoma.

Stanford Investigator(s)


Inclusion Criteria:

   - Pathological diagnosis of peripheral T-cell lymphoma of one of the following
   histologies as per the REAL classification: peripheral T-cell lymphoma (unspecified),
   anaplastic large cell lymphoma CD30+, angioimmunoblastic T-cell lymphoma, nasal/nasal
   type T/NK cell lymphoma, intestinal T-cell lymphoma, hepatosplenic T-cell lymphoma,
   subcutaneous panniculitic T-cell lymphoma.

   - Treatment naïve except for prior radiation or a single cycle of CHOP.

   - Patients must have at least one clear-cut bidimensionally measurable site by physical
   exam and/or computed tomography.

   - Prior radiation therapy for localized disease is allowed as long as the irradiated
   area is not at the mediastinal area or at the only site of measurable disease. Therapy
   must be completed at least 4 weeks before the enrollment in study.

   - Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

   - At least 18 years of age.

   - Adequate bone marrow reserve, indicated by absolute neutrophil count (ANC) > or equal
   to 1000/microL, platelets > or equal to 50,000/microL (25,000/MicroL if
   thrombocytopenia secondary to bone marrow involvement by lymphoma), and hemoglobin >
   or equal to 8 g/dL.

   - Adequate liver function, indicated by bilirubin < or equal to 1.5 times the upper
   limit of normal (ULN), alanine transaminase (ALT) < or equal to 2 times the ULN or
   aspartate transaminase (AST) < or equal to 2.0 times the ULN, and albumin > or equal
   to 3.0 g/dL.

   - Adequate renal function, indicated by serum creatinine < or equal to 2.5 mg/dL.

   - Women of childbearing potential and sexually active males agree to use an accepted and
   effective method of contraception.

   - Able to give informed consent.

Exclusion Criteria:

   - Diagnosis of Mycosis Fungoides or Sezary Syndrome.

   - Active Hepatitis B or Hepatitis C infection.

   - Known HIV infection (HIV testing is not required).

   - Patients with active infections requiring specific anti-infective therapy are not
   eligible until all signs of infections have resolved and any continuing treatment if
   appropriate is given on an outpatient basis.

   - Previous doxorubicin therapy with cumulative dose of >100 mg/m2.

   - Left Ventricular Ejection Fraction (LVEF) < 50%.

   - Patients who are pregnant or breast-feeding.

   - Prior invasive malignancies within past 5 years.

   - Allergy to or history of allergy to diphtheria toxin or IL-2.

   - Preexisting severe cardiovascular disease (e.g. CHF, Severe CAD, cardiomyopathy, MI
   within the past 3 months, arrhythmia) requiring ongoing treatment.

   - Ongoing antineoplastic chemotherapy, radiation, hormonal (excluding contraceptives) or
   immunotherapy, or investigational medications within past 30 days.

   - Patients with deep vein thrombosis within 3 months.


drug: Denileukin diftitox

drug: Cyclophosphamide

drug: Doxorubicin

drug: Vincristine

drug: Prednisone

other: Pegfilgrastim

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Sipra Choudhury

New Trial Alerts

Receive email alerts when trials open to patients.